ESR2 and colorectal cancer: Interestingly, NDRG2 in colorectal cancer could affect the complex components of ubiquitin-protein ligase E3A (UBE3A) and estrogen receptor beta (ERβ), reducing the ubiquitin-mediated proteasome degradation of ERβ, demonstrating that NDRG2 could bind to UBE3A to hinder the binding of UBE3A to ERβ [26].